Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Akari Therapeutics announced a strategic research collaboration with WhiteHawk Therapeutics to combine their proprietary PH1 spliceosome-modulating payload with WhiteHawk's TOP1 inhibitor ADC platform. This collaboration aims to develop dual-payload antibody drug conjugates (ADCs) to expand therapeutic opportunities in oncology. The company also hi…